Trial Profile
A Phase I, Randomised, Double-blind, Placebo-controlled Study to Determine Pharmacodynamic Effects and Pharmacokinetics of a Single Oral Dose of 320 mg KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor Overactivity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ritobegron (Primary)
- Indications Detrusor instability; Spinal cord injuries
- Focus Pharmacodynamics
- Sponsors Boehringer Ingelheim
- 14 Oct 2014 New trial record